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Abstract
Familial hypercholesterolaemia is an autosomal dominant inherited disorder characterised by elevated low-density lipo-
protein cholesterol levels and consequently an increased risk of atherosclerotic cardiovascular disease (ASCVD). Familial
hypercholesterolaemia is relatively common, but is often underdiagnosed and undertreated. Cardiologists are likely to
encounter many individuals with familial hypercholesterolaemia; however, patients presenting with premature ASCVD
are rarely screened for familial hypercholesterolaemia and fasting lipid levels are infrequently documented. Given that
individuals with familial hypercholesterolaemia and ASCVD are at a particularly high risk of subsequent cardiac events,
this is a missed opportunity for preventive therapy. Furthermore, because there is a 50% chance that first-degree
relatives of individuals with familial hypercholesterolaemia will also be affected by the disorder, the underdiagnosis of
familial hypercholesterolaemia among patients with ASCVD is a barrier to cascade screening and the prevention of
ASCVD in affected relatives. Targeted screening of patients with ASCVD is an effective strategy to identify new familial
hypercholesterolaemia index cases. Statins are the standard treatment for individuals with familial hypercholesterolaemia;
however, low-density lipoprotein cholesterol targets are not achieved in a large proportion of patients despite treatment.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to reduce low-density lipoprotein
cholesterol levels considerably in individuals with familial hypercholesterolaemia who are concurrently receiving the
maximal tolerated statin dose. The clinical benefit of PCSK9 inhibitors must, however, also be considered in terms of
their cost-effectiveness. Increased awareness of familial hypercholesterolaemia is required among healthcare profes-
sionals, particularly cardiologists and primary care physicians, in order to start early preventive measures and to
reduce the mortality and morbidity associated with familial hypercholesterolaemia and ASCVD.
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Introduction
Familial hypercholesterolaemia (FH) is an autosomal
dominant inherited lipid disorder that, in most cases, is
caused by mutations occurring in one (or more) of three
genes: the low-density lipoprotein (LDL) receptor gene
(LDLR), the apolipoprotein B gene (APOB) and the
proprotein convertase subtilisin/kexin type 9 gene
(PCSK9).1 Mutations in these genes lead to impaired
LDL metabolism and elevation of plasma LDL-choles-
terol. FH can also be caused by mutations in other
genes, including signal transducing adaptor family
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member 1 (STAP1);2 however, mutations in such genes
are rare. Regardless of the underlying cause, patients
with FH have elevated LDL-cholesterol levels and are
therefore at increased risk of premature atherosclerotic
cardiovascular disease (ASCVD). ASCVD most
commonly manifests as coronary heart disease
(CHD),3 but patients may also present with stroke.4
Recent studies have shown that the prevalence of
heterozygous FH (HeFH) is one in 200–250 people5,6
and that of homozygous FH (HoFH) is one in 160,000–
300,000 people.7 Although HeFH is not uncommon, it
is often underdiagnosed and undertreated. This leads to
substantial mortality and morbidity;6 approximately
50% of men and 30% of women with FH will develop
CHD before the age of 50 years if the disorder is left
untreated.3 ASCVD in patients with FH is therefore an
important public health challenge. Patients with con-
ﬁrmed FH should receive high-intensity lipid-lowering
therapy (LLT), which has been shown to improve their
life expectancy8 and quality of life markedly.9
As a result of the high prevalence of ASCVD in
patients with FH, it is important that individuals pre-
senting with ASCVD are assessed for FH.10 However,
screening for FH among this patient population
remains low,5 which leads to suboptimal management
of patients with FH and ASCVD. Furthermore, given
the autosomal dominant inheritance of FH, family
members of individuals diagnosed with FH should be
screened in a cascade approach to identify aﬀected rela-
tives. As the prevalence of FH is much greater in those
presenting with ASCVD than in the general popula-
tion,5,11 patients with ASCVD represent a key target
population for FH screening.5 It is, therefore, vital
that cardiologists and other medical professionals are
aware of current guidelines and consensus statements
on the diagnosis and treatment of patients with FH.6,7,9
Understanding of the molecular pathology and genetic
basis of FH is vital to support screening so that LLT is
initiated in individuals with FH in order to prevent
ASCVD events.12
Cardiovascular disease risk in patients
with FH
Patients with FH are up to 16 times more likely to
develop ASCVD than the overall population.13–16 In
a population-based cohort study comprising 69,016
individuals from Denmark, it was estimated that 33%
of patients with FH had CHD.13 Patients with FH typ-
ically develop premature ASCVD, with ASCVD events
often occurring in patients with HeFH before 55 years
of age in men and before 60 years of age in women.6 A
recent cohort study of CHD risk in patients with FH,
which included 65,565 people and a follow-up of
78,985–308,378 person-years, found that CHD risk
was accelerated in patients with FH by 10–20 years in
men and 20–30 years in women.17 ASCVD is a leading
cause of death in those with FH;18 in a 21-year cohort
study of 5518 patients with FH, ASCVD was the most
common cause of death, accounting for 42% of the 189
deaths occurring during the study period.19
Given the relative rarity of HoFH (estimated preva-
lence is one in 160,000–300,000 people),7 little is known
about the exact ASCVD risk and associated mortality
in these patients.20 Sjouke et al. found that 29% of 49
patients with HoFH had ASCVD.21 Patients with
HoFH develop ASCVD much younger than those
with HeFH, often before 20 years of age. In a study
of 149 patients with HoFH, Raal et al. found that, in
those who were untreated, the age (mean SD) at ﬁrst
non-fatal major adverse cardiac event (MACE) was
12.8 5.9 years and the age of ASCVD-related death
was 17.7 10.1 years.22
Cardiovascular disease risk stratification
Not all patients with FH develop atherosclerosis and
ASCVD to the same extent.23 ASCVD risk depends
mainly on plasma LDL-cholesterol levels.24 The
underlying genetic mutation, patient comorbidities
and lifestyle factors inﬂuence LDL-cholesterol levels
and ASCVD risk.23 Stratiﬁcation of patients by their
individual ASCVD risk factors may help to identify
those who would beneﬁt from high-intensity LLT.25
Mutation of a known FH-causing gene can be found
in approximately 80% of patients with deﬁnite FH.23
Among patients with an identiﬁable genetic mutation,
the most common cause of FH is mutations in LDLR,
aﬀecting over 90% of these patients.6 These fall into six
classes: class 1 mutations are null mutations that result
in no detectable LDLR protein; class 2 mutations dis-
rupt the transport of LDLR from the endoplasmic
reticulum to the Golgi apparatus; class 3 mutations
lead to the expression of non-functional LDLR; class
4 mutations result in LDLR–LDL complexes that
cannot cluster in coated pits; class 5 mutations lead to
ineﬃcient recycling of LDLR; and class 6 mutations
disrupt the targeting of the receptor to the basolateral
membrane.9
Null mutations in LDLR are consistently found to
be associated with the most severe forms of FH (in
terms of both LDL-cholesterol levels and ASCVD
risk).21,26,27 In a study of 1088 patients with premature
myocardial infarction (MI), it was found that, com-
pared with the general population, those with a class
1 mutation in LDLR had a 13-fold increased risk of
MI, while those with other classes of LDLR mutations
had a 2.4-fold increased risk.14 Furthermore, LDLR
mutations overall confer a more severe phenotype
than APOB mutations. In a study of CHD risk in
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patients with FH and their unaﬀected relatives, individ-
uals with any class of LDLR mutation had a 8.5-fold
increased risk of CHD, whereas those with an APOB
mutation had a 2.7-fold increased risk compared with
unaﬀected relatives.28
Mutations in APOB occur in 5–10% of patients with
FH.1 However, the frequency of mutation in this gene
varies by country and has not been found to occur in
Finland, Spain, Russia and Japan.29 The most frequent
FH-causing mutation in this gene is the R3500Q
(Arg3500Gln) mutation.1 Patients carrying this muta-
tion have been shown to have signiﬁcantly increased
LDL-cholesterol levels and a seven times increased
risk of ischaemic heart disease compared with the
general population.30 Not all mutations in APOB are
associated with FH; for example, patients with the
R3531C (Arg3531Cys) mutation have been shown not
to have an increased risk of ischaemic heart disease
compared with the general population.30
Mutations in PCSK9 are relatively rare, occurring in
fewer than 1% of patients with HeFH,31 which makes it
diﬃcult to obtain suﬃcient data to assess the
magnitude of the ASCVD risk speciﬁcally associated
with mutations in this gene.32 More than 20 diﬀerent
mutations have been identiﬁed in PCSK9 and all of
these have diﬀerent eﬀects on lipid levels and ASCVD
risk.6,33 In a study of 130 patients with FH without
mutations in LDLR or APOB, it was found that diﬀer-
ent mutations in PCSK9 cause variable phenotypes,
and that the type and severity of hyperlipidaemia and
level of ASCVD risk could vary among individuals
from the same family.33 Furthermore, one particular
mutation in PCSK9 has been shown to be associated
with a very severe phenotype; in a retrospective analysis
of 49 patients with FH, over a 30-year follow-up
period, individuals carrying the D374Y (Asp374Tyr)
PCSK9 mutation were aﬀected by premature CHD
more than 10 years earlier than those with severe muta-
tions in LDLR.34
The degree of elevation of LDL-cholesterol is the
main factor driving ASCVD risk in patients with FH,
and those with LDL-cholesterol levels greater than
10mmol/L are at particularly high risk.7,25 In addition
to LDL-cholesterol, lipoprotein a (Lp[a]) has recently
been identiﬁed as a possible independent risk factor for
ASCVD, both in the general population and in patients
with FH. In a cross-sectional analysis of 1960 patients
with FH and 957 relatives without FH, patients with
FH had higher plasma levels of Lp(a) than their unaf-
fected relatives. In individuals with FH, ASCVD-free
survival was signiﬁcantly lower in patients who had
Lp(a) levels above 50mg/dL than in those with Lp(a)
levels below 50mg/dL.26 Furthermore, in a recent pro-
spective cohort study of 46,200 individuals, patients
with FH and high Lp(a) levels had the highest risk of
MI; compared with individuals without FH and lipo-
protein(a) concentrations of 50mg/dL or less, hazard
ratios (HRs) for MI were 1.4 for those without FH
and Lp(a) levels above 50mg/dL, 3.2 for those with
FH and Lp(a) levels of 50mg/dL or less and 5.3 in
those with FH and Lp(a) levels above 50mg/dL.35
Other ASCVD risk factors that apply to the general
population also play a role in ASCVD risk in patients
with FH, but their predictive value diﬀers from that of
the general population.23 These factors include diabetes
mellitus, obesity, hypertension, smoking, renal
insuﬃciency, low high-density lipoprotein (HDL)-chol-
esterol levels, and a family history of premature
ASCVD.26,36–39 A family history of premature
ASCVD in a patient with FH probably reﬂects the
autosomal dominant inheritance of the disorder.
Thus, it is important to take a family history of prema-
ture ASCVD events to gain a full picture of ASCVD
risk. Similar to the general population, male sex
increases the risk of premature ASCVD in the FH
population: men with FH have been shown to develop
ASCVD approximately 7 years earlier than women
with FH.36,40 This diﬀerence in ASCVD risk is
probably driven by the cardioprotective eﬀects of oes-
trogen.41 In addition, high levels of testosterone may be
linked to premature ASCVD,42 but the relative contri-
bution of this factor has not been established in patients
with FH. Clinical characteristics speciﬁc to patients
with FH, such as the presence of tendon xanthomas,
do not appear to be independently associated with
ASCVD risk in individuals with FH.39
Subclinical atherosclerosis in the coronary arteries is
an independent risk factor for ASCVD in the general
population.43 This is also the case in patients with FH;
a recent prospective study of 101 patients with HeFH,
in whom 21 MACEs occurred during a median follow-
up of 941 days, found that an increased coronary ath-
erosclerotic plaque score was independently associated
with coronary events.44 Non-invasive imaging
techniques, such as ultrasonography and computed
tomography, can be used to determine the extent of
subclinical atherosclerosis.45 Use of such tests could
help to identify patients with FH and advanced athero-
sclerosis who may be at high risk of ASCVD.25
Risk calculators, such as the US Framingham risk
score and the European SCORE (systematic coronary
risk evaluation), are not suitable for those with FH
because these patients are at considerably higher risk
of ASCVD due to lifelong exposure to elevated plasma
LDL-cholesterol levels.6 Evidence of the suitability of
existing criteria for assessing the ASCVD risk in
patients with FH is limited. Therefore, the
International Atherosclerosis Society Severe Familial
Hypercholesterolemia Panel has provided a consensus
statement, based on expert opinion, that suggests the
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following criteria to identify patients with severe FH
who are at high risk of ASCVD: patients with LDL-
cholesterol levels above 10mmol/L (>400mg/dL) at
diagnosis, or greater than 8mmol/L (>310mg/dL) or
5mmol/L (>190mg/dL) at diagnosis if another one or
two risk factors, respectively, are present (i.e. age >40
years, smoking, male sex, high Lp(a) (>75 nmol/L), low
HDL-cholesterol (<1mmol/L), hypertension, diabetes
mellitus, impaired renal function, body mass index
(BMI) >30 kg/m2, family history of premature
ASCVD). Patients with advanced subclinical athero-
sclerosis or those who have previously experienced a
cardiovascular event should also be considered as
having severe FH and being at high risk of ASCVD.25
Underdiagnosis and undertreatment
FH is common among patients presenting with
ASCVD.10The European Action on Secondary and
Primary Prevention by Intervention to Reduce Events
(EUROASPIRE) IV cohort study of 7998 individuals
with CHD across 24 European countries found that,
among 7044 evaluable patients, 8.3% had potential
FH (deﬁned as a score of 6 using a modiﬁed version
of the make early diagnosis to prevent early deaths
(MEDPED)/World Health Organization (WHO)
criteria and the Dutch Lipid Clinic Network (DLCN)
diagnostic criteria).5 Rates of potential FH in patients
with CHD varied considerably across European
regions, ranging from as low as 3.4% in the Finnish
centres to 20.8% in Bosnia and Herzegovina. These
large regional diﬀerences in FH prevalence may relate
to genetic founder eﬀects.46–48 In addition, the types of
centres participating in the study in each region may
have impacted on the reported FH prevalence.5
Lifestyle factors, such as variations in lipid intake
across regions,49 may also lead to misdiagnoses of FH
in some countries.
The EUROASPIRE IV study found that FH preva-
lence in individuals with CHD was inversely related to
age; the prevalence of potential FH was eight times
greater in patients younger than 50 years than in
those older than 70 years.5 This association with age
may partly be explained by the fact that patients with
FH die earlier resulting in a decline of the prevalence of
potential FH by age.5 Furthermore, CHD occurred
prematurely in 78% and 73% of men and women
with potential FH, respectively, compared with 33%
in men and 37% in women without FH.5 Similarly, in
a smaller cohort study of 4778 patients with acute cor-
onary syndromes (ACSs), FH prevalence (deﬁned by
the Simon Broome Register and DLCN diagnostic cri-
teria) inversely correlated with age of ACS onset.10
These recent studies reﬂect the results of seminal
work from Genest et al. in 1992, who found that
more than half of patients with premature CHD had
a familial lipoprotein disorder.11
Prevention of ASCVD in individuals with FH is
failing, partly because of underdiagnosis in this patient
population. Yudi et al. conducted a retrospective ana-
lysis of 210 patients admitted to hospital in Australia
for premature coronary artery disease (events occurring
in male patients aged 55 years and female patients
aged 60 years) in a 12-month period, which found
that only 96 patients (46%) had their fasting lipid
levels recorded following a hospital admission for
premature coronary artery disease.50 Among individ-
uals for whom lipids were measured, three (1%) were
found to have probable FH and 50 (24%) had possible
FH, as assessed using the DLCN criteria.50 In a
Norwegian registry study of 5538 patients with geno-
type-veriﬁed FH, 1411 patients were hospitalised over a
15-year period; ischaemic heart disease was reported in
the hospitalisation of 90% of these patients. However,
the diagnosis of FH was registered in only 46% of the
patients at discharge.51
The underdiagnosis of FH among individuals with
ASCVD has led to inadequate administration of ther-
apy to prevent further ASCVD events. In the
Australian study by Yudi et al., 23% of individuals
with retrospectively diagnosed possible or probable
FH were discharged from hospital without LLT.50
Furthermore, data from the EUROASPIRE IV study
showed that only 55% of patients with CHD and
potential FH received high-intensity statin therapy,5
and data from the Danish study by Benn et al.
showed that only 48% of patients with clinically
deﬁned FH received LLT.13 Even in patients who are
receiving LLT, the therapy may not be suﬃcient to
reduce ASCVD risk adequately; a recent observational
study, conducted in Europe, China, Canada, Russia,
Africa and the Middle East, which included 54,811
patients receiving statin therapy found that 60.1% of
patients with probable FH had CHD, compared with
38.8% of those in the total study population.52 Taken
together, the results of these studies suggest that
patients with ASCVD are receiving suboptimal treat-
ment. Given that appropriate treatment can reduce the
risk of ASCVD, the issues of underdiagnosis and
undertreatment of FH and ASCVD require attention.53
Until recently, however, there were few available agents
with the potency and tolerability needed to treat FH
adequately.
In many patients with FH, the disease only becomes
evident after the ﬁrst major cardiovascular event and
cardiologists are, therefore, frequently the ﬁrst to diag-
nose a patient with FH.54 A lack of awareness among
cardiologists of the relatively high prevalence of FH in
patients with ASCVD may account for the low level of
FH screening in these individuals. In a survey
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conducted among American College of Cardiology
CardioSurve members in 2011, the majority of whom
had over 10 years of experience in cardiovascular
clinical practice, most (80%) were unaware of the
true prevalence of FH. Although more than 95% of
cardiologists surveyed agreed that patients with FH
are at a moderate/high risk of future ASCVD events,
only 10% reported feeling very or extremely conﬁdent
about their understanding of FH.55 Furthermore, fewer
than 30% of cardiologists recognised FH when they
were shown a case brought by the National Lipid
Association.55 The survey also revealed a lack of under-
standing of the genetic causes of FH; 60% of cardiolo-
gists were unaware of the fact that, given the autosomal
dominant mode of inheritance, there is a 50% chance
that ﬁrst-degree relatives of a patient with FH will also
have the disorder.55 Increased awareness of FH among
cardiologists is required to improve the diagnosis of this
condition in patients with ASCVD and to facilitate ini-
tiation of appropriate treatment earlier in the disease
course. Moreover, increasing the understanding of the
genetic basis of FH may support cardiologist-led initi-
ation of screening and ASCVD prevention by referral
of a patient’s relatives to primary care physicians or
lipid specialists.
Screening
As a result of the prevalence of FH, a systematic
approach to screening is warranted. Cascade screening,
whereby ﬁrst, second and third-degree relatives of an
established index case are assessed for FH via genetic
testing and LDL-cholesterol measurement, has been
shown to be a cost-eﬀective approach.56 Targeted
screening in selected groups that have a high prevalence
of FH, such as patients presenting with premature
ASCVD, is an eﬃcient method of identifying new FH
index cases.57 Universal screening, in which a popula-
tion is systematically screened, could be applied to FH
via cholesterol measurement or genotyping of children.
Although this approach has not been used in FH, uni-
versal screening has been successful in detecting other
disorders such as phenylketonuria and cystic ﬁbrosis.58
Universal genotyping may not identify patients whose
FH is caused by novel mutations or polygenic muta-
tions and may be most eﬀective in populations in which
genetic founder eﬀects restrict the number of prevalent
mutations.57 Data suggest, however, that it may be pru-
dent to initiate cholesterol screening in children, in
whom elevated levels of LDL-cholesterol alone are
strongly diagnostic of FH.59 In addition, screening of
children has been shown to be an eﬀective method for
the diagnosis of aﬀected parents and siblings through a
cascade approach.60 Furthermore, identifying FH in
childhood enables treatment to be initiated early,
which could result in improved long-term outcomes
for patients, although research is needed to ascertain
the exact age to begin treatment and the long-term
safety of LLTs.61
Unfortunately, screening programmes are not
conducted on a large scale in most countries. Slovenia
initiated universal genetic screening for FH among
5-year old children in 2009.62 A national cascade
screening programme has been conducted in the
Netherlands,63 and several countries, including Spain,
the UK and Norway, have regional screening
programmes.64,65 In addition, a pilot screening
programme has recently started in Croatia (I Pec´in,
personal communication). It is important to note that
the eﬀectiveness of screening programmes varies and
there is disparity in detection levels between countries,
ranging from 20% of patients with conﬁrmed FH in
Spain to 36% in the Netherlands and 39% in
Slovenia.6,62,64 To improve detection levels in Spain, a
national cascade screening approach has recently been
advocated.66 Further improvements, in both the
number of countries with screening programmes and
the eﬀectiveness of established screening programmes,
are required to tackle the ASCVD burden associated
with FH (Figure 1).
Diagnosis rates were based on the following
estimated prevalences: 1/500 Austria, Finland, France,
Germany, Italy, Portugal, Spain, UK, Switzerland; 1/
300 Belgium, Czech Republic, Netherlands, Norway; 1/
250 Greece, Poland, Sweden; 1/200 Denmark and
Slovenia.62,64 Please note, because of a lack of data
availability on FH prevalence in Austria and
Germany a 1/500 rate has been applied for these
countries.
Lack of awareness of FH prevalence may contribute
to the absence of nationwide screening programmes in
many countries. It is also likely that the initial cost of
implementing such programmes acts as a barrier to
their establishment and use; however, screening for
FH has been shown to be cost-eﬀective. In an
Australian study it was estimated that genetic cascade
screening for FH would reduce the 10-year incidence of
CHD from 50% to 25% among people with FH, lead-
ing to a gain of 29 quality-adjusted life-years for every
100 individuals screened.67 Understanding the long-
term beneﬁts in terms of quality of life and healthcare
resource utilisation associated with early diagnosis of
FH and prevention of ASCVD may act as an incentive
for screening programmes to be initiated. Further
support for genetic cascade screening in FH recently
came from a study analysing FH severity in patients
diagnosed with FH as part of the Netherlands cascade
screening programme. This study showed that the dele-
terious eﬀect of FH, both in terms of LDL-cholesterol
levels and ASCVD risk is the same in people distantly
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related to the index patient compared with those who
are more closely related, suggesting that FH severity is
mainly determined by the underlying mutation.68
Electronic screening of patient medical records may
be a further cost-eﬀective approach to increase the rate
of diagnosis of FH in primary care.69,70 For example,
Troeung et al. retrospectively screened the primary care
medical records of 3708 patients using the TARB-Ex
electronic screening tool, which extracts routine clinical
information from electronic medical records to derive a
DLCN criteria score and identify patients at risk of
FH, who may therefore require clinical investigation.69
The records of patients with potential FH (DLCN
score 5) identiﬁed by TARB-Ex were then reviewed
by a primary care physician and a lipid specialist;
patients subsequently considered to be at high risk of
FH were recalled for clinical assessment. The TARB-Ex
identiﬁed 32 patients at risk of FH compared with 22
identiﬁed by a physician-led manual review of medical
records, which was considered the ‘gold standard’ for
FH screening in this study. Sensitivity was 95.5%, spe-
ciﬁcity was 96.7%, negative predictive accuracy was
99.7% and positive predictive accuracy was 65.6%.
Ten patients were recalled for clinical examination,
seven of whom attended. Six of these patients were
diagnosed with phenotypic FH according to clinical
criteria and one patient was referred for FH genetic
testing. Electronic screening with TARB-Ex was com-
pleted in 10minutes, compared with 60 hours for
manual record review.
International and national patient registries collect
data on individuals with FH in a systematic and
standardised manner. This information can be useful
for understanding the epidemiology of the disorder
and risk factors associated with the development of
ASCVD, as well as for recruiting for clinical trials,
improving healthcare services, facilitating patient educa-
tion and identifying gaps in knowledge.71 Through
cascade screening, such registries also support the cost-
eﬀective identiﬁcation of additional patients with
FH.71,72 Examples of FH registries include international
registries such as the European Atherosclerosis Society
(EAS)-FH Studies Collaboration, the 10 Countries
Project and the ScreenPro FH programme, the HoFH
(a) (b)
<5% 5–10% 11–20% 21–30% 31–40% National screening program Regional screening
National FH registry
b a
b
Cascade screening
a
Figure 1. (a) FH diagnosis rates and (b) map of FH current screening programmes, ongoing or planned, across Europe.
FH: familial hypercholesterolaemia.
aCascade screening planned.
bLimited cascade screening.
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International Clinical Collaborators (HICC) registry,
and national registries such as the DLCN, Spanish FH
Foundation, Lipid TransPort Disorders Italian Genetic
Network (LIPIGEN, Italy), CASCADE FH Registry
(USA), SWEDEHEART (Sweden), the Czech
MEDPED database and the Portuguese FH
Study.64,73–75 Several countries, including Austria,
Greece and Poland, have recently established new
national FH registries, with the aim of increasing aware-
ness of FH and stimulating the initiation of nationwide
screening programmes.64 Furthermore, the international
EAS-FH Studies Collaboration (FHSC), which aims to
disseminate information on the detection and manage-
ment of FH, is a ﬁrst step towards creating a global
consensus on best practice in FH diagnosis and
treatment.64
Diagnosis
For screening programmes to be eﬀective, physicians
need to be aware of the diagnostic criteria for FH.
Several clinical criteria algorithms are used to diagnose
FH (Table 1). The DLCN criteria are widely accepted
and can be used to estimate the likelihood of FH.76 The
Simon Broome Register diagnostic criteria18 and the
MEDPED/WHO criteria77,78 are also used. In routine
clinical practice, however, some data needed for the
diagnostic algorithms may be inaccurate or incomplete
(e.g. detailed family history of ASCVD, xanthomas).79
It is important to note that diagnostic criteria are likely
to diﬀer by geographical region because certain clinical
presentations of FH vary across diﬀerent patient popu-
lations; for example, xanthelasmas have been shown to
occur in 32% of patients with FH in Finland compared
with 8% of patients in Norway.80 In addition, with the
increased use of LLTs among the general population,
some characteristics of FH may be masked preventing
diagnosis of FH in the assessed individual as well as in
aﬀected family members. In recognition of this issue,
Haralambos et al. recently developed modiﬁed FH
diagnostic criteria based on the DLCN criteria that
additionally provide a LDL-cholesterol correction
factor to estimate pretreatment LDL-cholesterol levels
in patients receiving LLT.80 It goes without saying that
secondary causes of hypercholesterolaemia, such as
nephrotic syndrome, hypothyroidism, diabetes mellitus,
or medication, must be excluded prior to applying any
of the above algorithms.1,81
Simpliﬁed diagnostic criteria would facilitate the
identiﬁcation of patients with FH. The recent publi-
cation of the familial hypercholesterolaemia ascertain-
ment tool (FAMCAT), which uses data collected
from primary care records, including total cholesterol
levels and family history of FH, may help clinicians
to identify patients with a high probability of having
FH. To facilitate routine identiﬁcation of patients
with FH, work is underway to integrate the
FAMCAT algorithm into the UK primary care com-
puter systems, supported by a user-friendly
interface.82
In addition, using clinical and genetic data from
64,106 patients who were screened for FH in the
Dutch FH screening programme, Besseling et al. devel-
oped a model to predict the presence of a FH-causing
mutation based on factors routinely collected in clinical
practice, including: age; sex; levels of LDL-cholesterol,
HDL-cholesterol and triglycerides; history of CVD and
age at onset; use of statins; smoking; alcohol; and pres-
ence of hypertension. Validation of the model in a sep-
arate patient cohort conﬁrmed that the model showed
good discrimination of patients at risk of FH. The
model will be available as an online calculator to aid
physicians in deciding whether or not to refer patients
for genetic testing.70
Genomic tests to identify pathogenic mutations in
LDLR, APOB and PCSK9 are also available and
may be considered the ‘gold standard’ for FH diagno-
sis; however, their use varies widely between countries,
probably owing to issues of cost and availability.6
Therefore, in clinical practice, FH is most commonly
diagnosed by clinical examination and laboratory tests,
because a high LDL-cholesterol level is the main clin-
ical factor contributing to an increased ASCVD risk,
and should be treated regardless of the results of muta-
tional analysis. Genetic testing may also have an impact
on issues related to life insurance reimbursement and
access to treatment.83 In the Netherlands, issues of gen-
etic discrimination have been circumvented by the
implementation of guidelines to protect patients with
FH under the Medical Examination Act (1998).84,85
When setting up screening programmes, countries
may also need to consider introducing relevant guide-
lines or laws to mitigate the potential for such genetic
discrimination.
Lipid targets for patients with FH
The aim of FH treatment is to reduce LDL-choles-
terol levels to prevent ASCVD. The 2016 joint
European Society of Cardiology and EAS guidelines
recommend target LDL-cholesterol levels of less than
3.5mmol/L (<135mg/dL) in children with FH over
10 years of age, a 50% reduction of LDL-cholesterol
at younger ages, less than 2.6mmol/L (<100mg/dL)
in adults with FH, or less than 1.8mmol/L (<70mg/
dL) in adults with FH in the presence of ASCVD.86
LDL-cholesterol targets apply for both HeFH and
HoFH; however, with current treatment options,
these are very diﬃcult to achieve in children and
adults with HoFH.6
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Table 1. FH diagnostic criteria.
(a) Dutch Lipid Clinic Network diagnostic criteria
Criteria Points
Family history
First-degree relative with prematurea ASCVD OR 1
First-degree relative with LDL-C 95th percentile for age and sex 1
First-degree relative with tendon xanthomas and/or arcus cornealis OR 2
Children 18 years old with LDL-C 95th percentile for age and sex 2
Clinical history
Patient with premature ASCVD 2
Patient with prematurea cerebral or peripheral vascular disease 1
Physical examination
Tendinous xanthomas 6
Arcus cornealis in patients 45 years old 4
LDL-C level, mmol/L (mg/dL)
8.5 (330) 8
6.5–8.4 (250–329) 5
5.0–6.4 (190–249) 3
4.0–4.9 (155–189) 1
DNA analysis
Functional mutation in LDLR, APOB or PCSK9 gene 8
Diagnosis (point total): definite FH, >8 points; probable FH, 6–8 points; possible FH, 3–5 points, unlikely FH, <3 points
(b) Simon Broome Register diagnostic criteria
Diagnosis of definite FH
Functional mutation in LDLR, APOB or PCSK9 gene
OR
Adult: cholesterol >7.5 mmol/dL or LDL-C >4.9 mmol/dL
Child:b cholesterol >6.7 mmol/dL or LDL-C >4.0 mmol/dL
PLUS
Tendon xanthomas in patient of first- or second-degree relative
Diagnosis of probable FH
Adult: cholesterol >7.5 mmol/dL or LDL-C >4.9 mmol/dL
Child:b cholesterol >6.7 mmol/dL or LDL-C >4.0 mmol/dL
PLUS
Family history of ASCVD: <60 years of age in a first-degree relative or <50 years of age in a second-degree relative
OR
Family history of raised total cholesterol level: >7.5 mmol/dL in an adult first- or second-degree relative or >6.7 mmol/dL
in a childb or sibling
(c) MEDPED diagnostic criteria
Total cholesterol cut-off points, mmol/dL
Age (years) First-degree relative
with FH
Second-degree
relative with FH
Third-degree
relative with FH General population
<20 5.7 5.9 6.2 7.0
20–29 6.2 6.5 6.7 7.5
30–39 7.0 7.2 7.5 8.8
40 7.5 7.8 8.0 9.3
Diagnosis is made if total cholesterol levels exceed cut-off points
APOB: apolipoprotein B gene; ASCVD: atherosclerotic cardiovascular disease; FH: familial hypercholesterolaemia; LDL-C: low-density lipoprotein
cholesterol; LDLR: low-density lipoprotein receptor gene; PCSK9: proprotein convertase subtilisin/kexin type 9 gene.
aPremature ASCVD, cerebral or peripheral vascular disease defined as occurring in males aged <55 years and in women aged <60 years.
b<16 years of age.
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Treatment options
Diet and lifestyle modifications
Diet and lifestyle have an eﬀect on LDL-cholesterol
levels and ASCVD risk.87,88 Patients with FH
should be counselled regarding lifestyle modiﬁcations
to reduce fat and cholesterol intake, to avoid tobacco
products, and to balance physical activity with caloric
intake to maintain a healthy BMI.1 It is important to
note that, although FH cannot be managed by diet and
lifestyle changes alone, healthy lifestyle modiﬁcations
should be used in conjunction with optimised LLT in
order achieve LDL-cholesterol targets and minimise
ASCVD risk.89
Statins and other LLTs
Statins are the cornerstone of treatment for patients
with FH; however, target LDL-cholesterol levels are
not reached in a large proportion of patients, despite
the use of statins and additional LLT.90 Statins lower
LDL-cholesterol by inhibiting 3-hydroxy-3-methylglu-
taryl-coenzyme A reductase, which results in upregula-
tion of the LDLR.91 The 2013 EAS consensus
statement recommends that patients with FH receive
high-dose statin treatment (atorvastatin 80mg/day,
rosuvastatin 40mg/day or pitavastatin 4mg/day) at
diagnosis.6 The eﬃcacy of statins in reducing morbidity
and improving survival rates in patients with FH has
been demonstrated in retrospective and cohort studies.
In a retrospective study, statins were shown to reduce
the risk of CHD by 76% in patients with FH who
received statins before the onset of CHD.53 In addition,
the results of a cohort study of 3382 patients with FH
indicated that treatment with statins resulted in a 37%
reduction in CHD mortality.92 There is, however, a
lack of data from randomised placebo controlled
trials on the clinical beneﬁt of statins in patients with
FH. Given the high risk of ASCVD in these patients,
such trials are not ethically justiﬁable. However, the
randomised placebo controlled Lipid Research Clinics
Coronary Primary Prevention Trial, which studied a
patient population that was likely to be enriched for
individuals with FH, may provide some insights into
the clinical beneﬁt of statins. The study showed that
patients receiving the statin cholestryramine had a
12% reduction in LDL-cholesterol and a 19% reduc-
tion in CHD risk compared with placebo-treated
patients.93 In addition, a real-world retrospective ana-
lysis of 2447 patients with HeFH found that moderate
to high-intensity statin therapy lowered the risk of
ASCVD and death by 44% compared with the risk in
patients who had never received statins.12
Despite the administration of high-dose potent sta-
tins, nearly 80% of patients with HeFH do not achieve
target LDL-cholesterol levels.90 These individuals
require additional agents to enable them to reach
these targets. Statin intolerance may contribute to an
insuﬃcient LDL-cholesterol response to therapy. There
is, however, a lack of data on the incidence of statin
intolerance and it is likely that non-adherence to statin
treatment is the main cause of suboptimal outcomes in
patients prescribed statins.94,95
Ezetimibe decreases cholesterol absorption at the
brush border of the small intestine by inhibiting
Niemann–Pick C1-like protein (NPC1L1)96 and can
be used in combination with statin therapy when
LDL-cholesterol targets have not been met with statin
monotherapy.6,86 Ezetimibe is useful in the manage-
ment of patients with HoFH because the mechanism
of action does not rely on LDLR expression.96
The clinical eﬃcacy of ezetimibe was questioned follow-
ing results from the Ezetimibe and Simvastatin in
Hypercholesterolemia Enhances Atherosclerosis
Regression (ENHANCE) trial, which showed that the
addition of ezetimibe to simvastatin led to a reduction
in LDL-cholesterol, but not to a reduction in carotid
intima–media thickness.97 Recent data from the
IMProved Reduction of Outcomes: Vytorin Eﬃcacy
International Trial (IMPROVE-IT), however, suggest
that the further reduction in cholesterol levels in
patients receiving ezetimibe provides clinical beneﬁt,
in terms of reducing both LDL-cholesterol levels and
cardiovascular events.98 Ezetimibe can also be pre-
scribed as monotherapy to individuals who are intoler-
ant to statins.99,100
Bile-acid-binding resins (cholestyramine, colestipol
or colesevelam) decrease the absorption of bile acid,
resulting in increased conversion of cholesterol to bile
acids and enhanced production of LDLR.96 For
patients with FH and established ASCVD, combin-
ation therapy with a statin, ezetimibe and a bile-acid-
binding resin is recommended.8,86
Statins are less eﬀective in patients with HoFH
than in those with HeFH due to the severely
decreased LDLR function in HoFH patients.101 The
therapy of choice for these patients is LDL apheresis
in combination with high-intensity statin treatment,
with or without ezetimibe.6,7 LDL apheresis should
also be considered in patients with HeFH who are
intolerant to statins or in whom LDL-cholesterol
levels and ASCVD risk remain high following
maximally tolerated LLT.102 Although apheresis
lowers LDL-cholesterol levels by 55–70%, the eﬀect
is transient and levels rebound to pre-apheresis
concentrations within a few days.103 In addition,
apheresis is expensive and time-consuming to admin-
ister, and therefore is not widely available.103
Lomitapide is a new LLT that inhibits the micro-
somal triglyceride transfer protein, which functions in
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the production of LDL. Phase 3 data from a single-
arm study in 29 patients with HoFH showed that, at
week 26, the addition of lomitapide to current LLT
reduced LDL-cholesterol levels by 50% from
baseline.104
Mipomersen is an antisense oligonucleotide that
inhibits APOB protein synthesis. In phase 3 trials, com-
pared with placebo, the addition of mipomersen to
maximally tolerated statin therapy (with or without
other LLTs) has been shown to reduce LDL-cholesterol
levels signiﬁcantly in patients with HeFH and CHD,105
and in patients with HoFH.106 Mipomersen is
approved in the USA in combination with LLTs for
the treatment of patients with HoFH.107 Approval
has not been granted in Europe as a result of hepatic
and cardiac safety concerns.108
Fibrates are agonists of peroxisome proliferator-
activated receptor-a, which via regulation of tran-
scription factors regulate various steps in lipid and
lipoprotein metabolism.86 In combination with the
maximum tolerated dose of statins, ﬁbrates can be
considered in patients with FH who have elevated
triglycerides and low HDL-cholesterol, or in those
with serum triglyceride levels greater than 5.7mmol/
L (>500mg/dL).6 However, it must be noted that the
lipid-lowering eﬀect of ﬁbrates is minimal, and with
more potent therapies now available, they are unli-
kely to be a standard treatment choice for patients
with FH.
Overall, current data suggest that the treatment of
patients with FH is often not optimal. In a population-
based cohort study, individuals with FH who were not
treated with LLT had a 13-fold increased risk of CHD
compared with those without FH. This risk was
reduced, to 10-fold, when LLTs were used.13 This high-
lights the need to monitor response to therapy and to
ensure that patients with FH are receiving treatment of
suﬃcient intensity. A 2-year prospective study of 325
patients with FH showed that high-intensity statin ther-
apy (high-dose atorvastatin) was more eﬀective at redu-
cing LDL-cholesterol levels and decreasing carotid
intima–media thickness than lower-intensity statin ther-
apy (simvastatin).109 Furthermore, pharmacokinetic
alterations have been reported when statins are co-
administered with drugs metabolised through the cyto-
chrome P450, 3A4 or 2C9 pathways (through which
most statins are metabolised). These changes could
lead to reduced eﬃcacy and an increase in adverse
events (AEs), making statins unsuitable for patients
who require certain concomitant medications.110,111
Novel treatments are required to prevent cardiovascu-
lar events eﬀectively in patients with FH, particularly in
individuals with established ASCVD or homozygous
mutations, and in those who are intolerant to statin
therapy.
PCSK9 inhibitors
Monoclonal antibodies that inhibit PCSK9 are a
promising treatment modality for patients with
FH.112 PCSK9 is a serine protease secreted by hepato-
cytes that binds to the LDLR and promotes its degrad-
ation.113 Monoclonal antibodies to PCSK9 prevent its
interaction with the LDLR and thereby restore LDLR
recycling and LDL-cholesterol uptake.114 A hint
towards a beneﬁcial eﬀect of PCSK9 inhibition was
derived from studies in patients carrying non-sense
mutations in PCSK9 that were found to be associated
with low LDL-cholesterol levels and a reduced risk of
CHD.115 Two antibodies to PCSK9, evolocumab and
alirocumab, were approved in 2015 in the USA,
Canada and Europe for the treatment of patients with
FH in whom target LDL-cholesterol levels are not
achieved with available therapies.116–120 Recently, the
global clinical development programme for a third
PCSK9 antibody, bococizumab, was discontinued
because of an unanticipated attenuation of eﬃcacy
over time associated with higher immunogenicity and
a higher rate of injection-site reactions than seen with
other agents in this class.121 RNA interference inhib-
ition of proprotein convertase subtilisin/kexin type 9
(PCSK9) is also being investigated.122 ALN-PCSsc is
a ﬁrst-in-class RNA interference that acts by switching
oﬀ PCSK9 synthesis in the liver.122 Promising eﬃcacy
and safety results have been reported in a phase 1 study
in healthy volunteers and in a recent phase 2 study in
patients at high risk of ASCVD who had elevated
LDL-cholesterol levels;123,124 however, phase 3 data
in patients with FH are required to evaluate the role
of this therapy in FH.
Evolocumab and alirocumab have shown eﬃcacy in
randomised controlled trials in reducing LDL-choles-
terol levels in patients with FH at high risk of develop-
ing ASCVD. Evolocumab has been evaluated in a
broad patient population, including individuals whose
LDL-cholesterol levels were not controlled by statin
therapy, patients with HoFH and those with severe ath-
erosclerosis. In the Reduction of LDL-cholesterol with
PCSK9 Inhibition in Heterozygous Familial
Hypercholesterolemia Disorder (RUTHERFORD)
phase 3 trial, 331 patients with HeFH whose LDL-cho-
lesterol levels were not adequately controlled with LLT
received evolocumab (140mg every 2 weeks or 420mg
monthly) in addition to current therapy. Following 12
weeks of treatment, LDL-cholesterol levels were
reduced by 60% in patients receiving evolocumab.
These patients also experienced a 30% reduction in
Lp(a) levels compared with those receiving placebo.125
This might have a large clinical impact because elevated
Lp(a) is an independent risk factor for ASCVD in
patients with FH.26,35 Evolocumab has also shown
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eﬃcacy in patients with HoFH. In the phase 3 Trial
Evaluating PCSK9 Antibody in Subjects with LDL
Receptor Abnormalities (TESLA) study involving 50
patients who received LLT but did not undergo apher-
esis, 12 weeks of treatment with evolocumab 420mg
monthly led to a signiﬁcant mean LDL-cholesterol
reduction of 31% compared with placebo.126
Alirocumab has shown eﬃcacy in reducing
LDL-cholesterol and Lp(a) levels in patients with
HeFH. In the multicentre, placebo controlled rando-
mised phase 3 trials ODYSSEY FH I and II, 735
patients with HeFH, with or without a history of
ASCVD, whose LDL-cholesterol levels were not con-
trolled by the maximum tolerated dose of statins, were
randomly allocated to receive alirocumab 75mg every 2
weeks, increasing to 150mg every 2 weeks if LDL-
cholesterol levels remained above 70mg/dL, or pla-
cebo. After 24 weeks, alirocumab treatment led to a
49% reduction in LDL-cholesterol levels, with 40%
of patients requiring the 150 mg dose.127
PCSK9 inhibitors have also shown promising results
in treating patients with FH whose LDL-cholesterol
levels are diﬃcult to control and for whom regular
LDL-cholesterol apheresis is required. In a small
study of three patients with FH and CHD, switching
from LDL-cholesterol apheresis to evolocumab main-
tained LDL-cholesterol lowering.128 After apheresis,
HDL-cholesterol levels increased and remained con-
stant on evolocumab treatment. Evolocumab was also
associated with a non-signiﬁcant trend towards
improved patient quality of life.128 The ODYSSEY
ESCAPE study assessed the eﬃcacy of alirocumab in
62 patients with severe HeFH who had been receiving
regular LDL-cholesterol apheresis for a mean of 7
years; 46% of patient receiving alirocumab and 62%
of those receiving placebo were also receiving a statin
therapy. Treatment with alirocumab 150mg every 2
weeks signiﬁcantly reduced the frequency of required
apheresis treatments by 75% (P< 0.0001) from week
7 to week 18. Apheresis was no longer required in
63% of patients receiving alirocumab compared with
0% of patients receiving placebo.129
As well as a strong eﬃcacy proﬁle, PCSK9 inhibitors
have been shown to be well tolerated. In the phase 3
RUTHERFORD trial, the rates of AEs with evolocu-
mab were similar to those seen with placebo. The most
common AEs in patients receiving evolocumab were
nasopharyngitis and muscle-related AEs, occurring in
9% and 5% of patients, respectively, compared with
5% and 1% of those receiving placebo, respectively.125
Injection-site reactions occurred at similar frequencies
in patients receiving evolocumab (6%) and in those
receiving placebo (4%). No patients discontinued treat-
ment because of an AE.125 As with evolocumab, similar
AEs were associated with alirocumab. In the phase 3
ODYSSEY FH I and II trials, the most common AEs
were injection-site reactions and nasopharyngitis.
Injection-site reactions occurred in 12% and 11% of
patients receiving alirocumab in ODYSSEY FH I and
FH II, respectively, compared with 11% and 7% of
those receiving placebo, respectively. Nasopharyngitis
occurred in 11% and 13% of those receiving alirocu-
mab in FH I and FH II, respectively, compared with
7% and 22% of those receiving placebo. Few patients
discontinued treatment because of AEs.127 A recent
meta-analysis on the long-term safety of PCSK9 inhibi-
tors suggested that PCSK9 inhibitors are not associated
with an increased risk of cumulative severe AEs, mus-
culoskeletal eﬀects or stroke compared with standard of
care.130 A subgroup analysis of larger outcome studies
found a two-fold increase in the incidence of neurocog-
nitive events with PCSK9 inhibitors compared with
standard of care.130 However, the results of the
non-inferiority EBBINGHAUS cognitive function
study, conducted in 1900 patients enrolled in the
Further Cardiovascular Outcomes Research With
PCSK9 Inhibition in Subjects With Elevated Risk
(FOURIER) study, found that evolocumab did not
increase the risk of impairment of cognitive function
compared with placebo.131
PCSK9 inhibitors have been shown to reduce LDL-
cholesterol levels, but their impact on long-term disease
progression and clinical outcomes is less well estab-
lished. The recent Global Assessment of Plaque
Regression with a PCSK9 Antibody as Measured by
Intravascular Ultrasound (GLAGOV) study of 968
patients with angiographic coronary disease assessed
the impact of PCSK9 inhibition on the progression of
coronary atherosclerosis. After 78 weeks, compared
with patients receiving statins and placebo, those
receiving evolocumab and statins had a signiﬁcantly
greater percentage reduction in atheroma volume
(0.95% vs. 0.05%; P< 0.0001) and absolute ather-
oma volume (5.8mm3 vs. 0.9mm3; P< 0.001).132
Although this study was not conducted in patients
with FH, these data suggest that the addition of evolo-
cumab to statin therapy could lead to signiﬁcant regres-
sion of atherosclerotic plaques. This could be beneﬁcial
for individuals with FH and ASCVD, if the results are
replicated in this patient population.
Preliminary long-term eﬃcacy data on PCSK9 inhibi-
tors preventing MACEs are also encouraging. In two
open-label randomised trials of evolocumab (OSLER-
1 and OSLER-2), 4465 patients, of whom 10% had FH,
received standard therapy or evolocumab (140mg every
2 weeks or 420mg monthly) plus standard therapy. At 1
year, patients receiving evolocumab had a signiﬁcant
reduction in the rate of MACEs compared with individ-
uals receiving standard therapy alone (0.95% vs. 2.18%;
P¼ 0.003).133 Similarly, in the phase 3 ODYSSEY Long
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Term trial of alirocumab, 2341 patients at high risk of
ASCVD, of whom 18%hadHeFH, received alirocumab
150mg every 2 weeks for 78 weeks.134 In a post hoc
analysis, the rate of MACEs was lower for patients
receiving alirocumab than for those receiving placebo
(1.7% vs. 3.3%; P¼ 0.02).
It should be noted, however, that in OSLER-1 and
OSLER-2 and ODYSSEY Long Term, the MACE
event numbers were very low in both the treatment
and control groups, and a longer follow-up period is
required to conﬁrm the long-term impact of PCSK9
inhibitors on the rate of MACEs. The results of such
prospective interim analyses give support to, but are
not proof of, the eﬃcacy of PCSK9 inhibitors in the
prevention of MACEs. Recently, the FOURIER trial
reported that at a median follow-up of 2.2 years
additional LDL-cholesterol lowering with evolocumab
(in combination with optimised statin therapy) signiﬁ-
cantly reduced the risk of cardiovascular events in
patients with ASCVD and high LDL-cholesterol
levels (1.8mmol/L) by 15% compared with placebo
(HR 0.85; P< 0.001).135 The ODYSSEY OUTCOMES
trial assessing the extent to which alirocumab reduces
the risk of MACEs is ongoing.136,137 In the phase 3
SPIRE-2 trial (median follow-up, 12 months) the now
discontinued PCSK9 inhibitor bococizumab signiﬁ-
cantly reduced MACEs in patients with a high risk of
MACEs (LDL-cholesterol 2.6mmol/L) compared
with placebo (HR 0.79; P¼ 0.02). However, in the
SPIRE-1 trial (median follow-up, 7 months) bococizu-
mab provided no beneﬁt compared with placebo in
patients at low risk of MACEs (LDL-cholesterol level
1.8mmol/L; HR 0.99; P¼ 0.94).138
As with all new treatments, the beneﬁt of PCSK9
inhibitors in patients with FH must be considered in
relation to their cost. A recent cost-eﬀectiveness ana-
lysis conducted in the USA determined that at their
2015 prices, PCSK9 inhibitors did not meet incremental
cost-eﬀectiveness thresholds.139 However, it must be
noted that the pricing structure and the cost-eﬀective-
ness model used in that analysis apply speciﬁcally to the
USA and are not applicable to other regions. Indeed, in
Europe the National Institute for Health and Care
Excellence has determined that both evolocumab and
alirocumab have favourable incremental cost-eﬀective-
ness ratios in patients with HeFH.140,141
Treatment: when to use PCSK9 inhibitors
Patients with FH and ASCVD, or another major risk
factor for ASCVD such as diabetes mellitus with target
organ damage or hypertension, or those with severe
HeFH should receive statins (preferably atorvastatin
or rosuvastatin) at the maximally tolerated dose plus
ezetimibe.142 Patients who have a less than anticipatedT
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response on maximally tolerated statin therapy (<50%
reduction in LDL-cholesterol) should be assessed for
adherence by evaluating the number of missed statin
doses per month and any barriers to adherence.
Patients who are unable to tolerate even a moderate-
intensity statin should be evaluated for statin intoler-
ance and considered for referral to a lipid specialist.143
Physicians should consider adding a PCSK9 inhibitor
to the regimen for patients with ASCVD, or a major
risk factor for ASCVD, if LDL-cholesterol levels are
more than 3.6mmol/L (>140mg/dL) or more than
2.6mmol/L (>100mg/dL) with evidence of rapid pro-
gression of ASCVD. Patients with severe HeFH with-
out ASCVD should be considered for PCSK9
inhibition therapy if LDL-cholesterol levels are more
than 5.0mmol/L (>200mg/dL) or more than
4.5mmol/L (>175mg/dL) in the presence of one or
more risk factors for ASCVD including diabetes melli-
tus, elevated lipoprotein levels (>50mg/L), hyperten-
sion and premature familial ASCVD. Most patients
with HoFH should receive maximal LLT including
LDL apheresis plus a PCSK9 inhibitor. However, it
should be noted that patients with a homozygous null
mutation in LDLR should not receive a PCSK9 inhibi-
tor.142 Treatment options for patients with HeFH and
HoFH are presented in Table 2.
Conclusions
FH is common in patients presenting with cardiovascu-
lar events, particularly when the events occur at an
early age. Screening for FH in individuals with
ASCVD is currently inadequate, leading to a missed
opportunity to initiate preventive therapies and to
reduce the morbidity and mortality associated with
FH. Primary care physicians are at the front line of
FH screening and thus need to be informed about the
prevalence of FH and how to diagnose the disorder so
that interventional treatments can be administered
before the onset of ASCVD. Cardiologists are likely
to encounter a large proportion of patients with FH
and with increased awareness and appropriate support,
they can make a substantial positive impact on out-
comes in these individuals. Ultimately, the care of
people with FH requires a multi-disciplinary approach
involving primary care physicians, lipid specialists, car-
diologists, nutritionists, nurses, pharmacists and
patient support groups. Statin therapy reduces LDL-
cholesterol levels and ASCVD risk, and treatment
with high-dose statins should be initiated in patients
with FH. For individuals at highest risk of developing
ASCVD, additional therapies are required to control
their disease adequately. Furthermore, data suggest
that patients with potential FH should also be treated
because the associated raised LDL-cholesterol levels
substantially increase the risk of ASCVD.5 New
PCSK9 inhibitors oﬀer an eﬀective and well tolerated
treatment option for patients with FH.
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